Article Details
Retrieved on: 2024-03-22 22:50:07
Tags for this article:
Click the tags to see associated articles and topics
Summary
The FDA authorized pemivibart (Pemgarda) for pre-exposure COVID-19 prophylaxis in immunocompromised individuals, relating to drug development, monoclonal antibodies, and immunology, specifically for variant-resistant cases.
Article found on: www.medpagetoday.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here